| An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment X Tekpli, T Lien, AH Røssevold, D Nebdal, E Borgen, HO Ohnstad, ... Nature communications 10 (1), 5499, 2019 | 157 | 2019 |
| Methylation profiling with a panel of cancer related genes: association with estrogen receptor, TP53 mutation status and expression subtypes in sporadic breast cancer JA Rønneberg, T Fleischer, HK Solvang, SH Nordgard, H Edvardsen, ... Molecular oncology 5 (1), 61-76, 2011 | 145 | 2011 |
| DNA methylation at enhancers identifies distinct breast cancer lineages T Fleischer, X Tekpli, A Mathelier, S Wang, D Nebdal, HP Dhakal, ... Nature Communications 8 (1), 1379, 2017 | 117 | 2017 |
| Intratumor heterogeneity defines treatment‐resistant HER 2+ breast tumors IH Rye, A Trinh, AB Sætersdal, D Nebdal, OC Lingjærde, V Almendro, ... Molecular oncology 12 (11), 1838-1855, 2018 | 112 | 2018 |
| The immune microenvironment in non‐small cell lung cancer is predictive of prognosis after surgery ÅK Öjlert, AR Halvorsen, D Nebdal, M Lund‐Iversen, S Solberg, ... Molecular oncology 13 (5), 1166-1179, 2019 | 73 | 2019 |
| SNP in TXNRD2 associated with radiation-induced fibrosis: a study of genetic variation in reactive oxygen species metabolism and signaling H Edvardsen, H Landmark-Høyvik, KV Reinertsen, X Zhao, ... International Journal of Radiation Oncology* Biology* Physics 86 (4), 791-799, 2013 | 55 | 2013 |
| miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer EM Lindholm, M Ragle Aure, MH Haugen, K Kleivi Sahlberg, ... Molecular oncology 13 (10), 2278-2296, 2019 | 39 | 2019 |
| Differential DNA methylation analysis of breast cancer reveals the impact of immune signaling in radiation therapy AR Halvorsen, Å Helland, T Fleischer, KM Haug, GI Grenaker Alnæs, ... International journal of cancer 135 (9), 2085-2095, 2014 | 38 | 2014 |
| miR-342-5p as a potential regulator of HER2 breast cancer cell growth EM Lindholm, SK Leivonen, E Undlien, D Nebdal, A Git, C Caldas, ... Microrna 8 (2), 155-165, 2019 | 35 | 2019 |
| A systematic comparison of copy number alterations in four types of female cancer F Kaveh, LO Baumbusch, D Nebdal, AL Børresen-Dale, OC Lingjærde, ... BMC cancer 16, 1-15, 2016 | 21 | 2016 |
| Genome-wide association study in breast cancer survivors reveals SNPs associated with gene expression of genes belonging to MHC class I and II H Landmark-Høyvik, V Dumeaux, D Nebdal, E Lund, J Tost, Y Kamatani, ... Genomics 102 (4), 278-287, 2013 | 17 | 2013 |
| Identification of microRNAs involved in pathways which characterize the expression subtypes of NSCLC AR Halvorsen, M Ragle Aure, ÅK Õjlert, OT Brustugun, S Solberg, ... Molecular oncology 13 (12), 2604-2615, 2019 | 13 | 2019 |
| Oslo Breast Cancer Research Consortium (OSBREAC) T Fleischer, X Tekpli, A Mathelier, S Wang, D Nebdal, HP Dhakal, ... DNA methylation at enhancers identifies distinct breast cancer lineages. Nat …, 2017 | 10 | 2017 |
| Oslo Breast Cancer Research Consortium (OSBREAC); Børresen-Dale, A T Fleischer, X Tekpli, A Mathelier, S Wang, D Nebdal, HP Dhakal, ... DNA methylation at enhancers identifies distinct breast cancer lineages. Nat …, 2017 | 9 | 2017 |
| Dynamic changes in the T cell receptor repertoire during treatment with radiotherapy combined with an immune checkpoint inhibitor ÅK Öjlert, D Nebdal, I Snapkov, V Olsen, J Kidman, V Greiff, J Chee, ... Molecular Oncology 15 (11), 2958-2968, 2021 | 7 | 2021 |
| Immune checkpoint blockade in the treatment of advanced non-small cell lung cancer–predictors of response and impact of previous radiotherapy ÅK Öjlert, D Nebdal, M Lund-Iversen, R Åstrøm Ellefsen, OT Brustugun, ... Acta Oncologica 60 (2), 149-156, 2021 | 7 | 2021 |
| and OSBREAC. An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment. Nat Commun. 2019; 10: 5499 X Tekpli, T Lien, AH Røssevold, D Nebdal, E Borgen, HO Ohnstad, ... PUBMED, 0 | 5 | |
| Proteome analysis of pancreatic tumors implicates extracellular matrix in patient outcome L Silwal-Pandit, SM Stålberg, HJ Johansson, G Mermelekas, IMB Lothe, ... Cancer Research Communications 2 (6), 434-446, 2022 | 2 | 2022 |
| Correction to: A systematic comparison of copy number alterations in four types of female cancer F Kaveh, LO Baumbusch, D Nebdal, AL Børresen-Dale, OC Lingjærde, ... BMC cancer 18, 2018 | 1 | 2018 |
| Preoperative profiles of plasma amino acids and derivatives distinguish periampullary cancer and benign disease SM Stålberg, L Silwal-Pandit, NE Bastani, DJH Nebdal, OC Lingjærde, ... BMC cancer 24 (1), 555, 2024 | | 2024 |
